On the strength of a five-year, $13.5 million dollar government grant, Northeastern University is establishing a center for nanomedicine where scientists from academia, industry, and government will work on treatments for cancer based on nanotechnology, which works at a scale one-thousandth the width of a human hair.
Northeastern University has been designated a Center of Cancer Nanotechnology Excellence by the National Cancer Institute, the university said today. Vladimir Torchilin, director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern’s Bouvé College of Health Sciences, will lead the new Center for Translational Cancer Nanomedicine. Its partners includes Beth Israel Deaconess Medical Center, Harvard Medical School, and Auburn University.
Researchers hope to create new drugs to target cancer cells, learn how nanocarriers deliver these drugs, and track how they travel through the body.
The National Cancer Institute has also given Northeastern professor and chair of pharmaceutical sciences Mansoor Amiji a five-year, $2.32 million grant to develop treatments based on nanoparticles for multidrug-resistant forms of lung and ovarian cancer. He is collaborating with researchers at Massachusetts General Hospital.
About white coat notes
|White Coat Notes covers the latest from the health care industry, hospitals, doctors offices, labs, insurers, and the corridors of government. Chelsea Conaboy previously covered health care for The Philadelphia Inquirer. Write her at firstname.lastname@example.org. Follow her on Twitter: @cconaboy.|
Gideon Gil, Health and Science Editor
Elizabeth Comeau, Senior Health Producer